openPR Logo
Press release

Exclusive interview with Robert Young released ahead of AI in Drug Discovery 2020

01-15-2020 03:17 PM CET | Health & Medicine

Press release from: SMi Group

AI in Drug Discovery 2020

AI in Drug Discovery 2020

SMi Reports: Industry expert and conference speaker, Robert Young, Principal, Blue Burgundy, was interviewed ahead of March’s AI in Drug Discovery conference.

SMi Group’s inaugural AI in Drug Discovery conference will take place on 16th-17th March in London. As the first AI in Drug Discovery event, it will highlight topics on AI machine learning technologies and its potential to reduce drug discovery costs by an estimated US$70 billion over the next decade, as well as explore how AI will pave a way to shorter, cheaper and more successful research and development.

SMi caught up with industry expert and conference speaker, Robert Young, Principal, Blue Burgundy, to find out more about his role in the industry, what he’s looking forward to at AI in Drug Discovery, and more.

Here is a snapshot of what was discussed:

How have you come to found your own company - the Blue Burgundy Drug Discovery Consulting Ltd - and what primary goals are you trying to achieve?
“I founded Blue Burgundy Drug Discovery Consulting when I took early retirement from GSK in July 2019. The aims of the consultancy are to harness my many years of drug discovery experience to identify the issues and opportunities in clients’ programmes, then to bring imaginative and innovative thinking to address them, without dogma, whilst looking to address the unique needs of every programme. Much of this will use my expertise in predictive design and trajectory mapping. Teaching and mentoring others will be an important element too.”

What would you say makes 2020 the ideal year for discussing AI in drug discovery?
The momentum and funding behind AI has burgeoned the past few years and it is now time to critically evaluate how chemists and machines can best work in harmony to add to add substance to the hype that the field has generated.

Can you tell us a little bit about your talk on synchronizing humans and computers? What you are hoping for attendees to take away from your talk?
“There are things the trained human brain can still do better than any algorithm – we can understand the scope and limitations of any fundamental calculations. My expertise lies in Physical Properties, the most fundamentally important descriptors in drug discovery, yet the way they are measured has fundamental flaws – so any predictive calculations will have compounding errors. And is it the Intrinsic or Effective lipophilicity of a molecule that actually matters?”

The full interview is available to download at www.AI-indrugdiscovery.com/openpr5

Rob will be presenting “Chemicals and Computers in Harmony: How to Surf the Wave?” on day one of the conference, covering:

• Drug Discovery is a game of establishing facts, recognising patterns and following principles.
• A chemist’s eyes, skill and experience can be augmented by good design and prediction.
• Don’t place your faith in models or models of models; treat/interpret data with caution.
• Compound quality is a destination not a journey.

As well as speaking at the main conference, Rob will be leading the half-day post-conference workshop ’Practical Application of Predictive Properties in Drug Design’ on Wednesday 18th March.

Interested parties can view the full agenda and book their place online at www.AI-indrugdiscovery.com/openpr5

AI in Drug Discovery Conference 2020
Main Conference: 16th-17th March 2020
Post-Conference Workshop: 18th March 2020
London, UK

--- ENDS –
Contact Information:
For media enquiries, contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 or hsidhu@smi-online.co.uk

India House, 45 Curlew Street

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exclusive interview with Robert Young released ahead of AI in Drug Discovery 2020 here

News-ID: 1897202 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug